A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 12, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Triple-Negative Breast NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Carcinoma, Squamous CellAdvanced Solid Tumors
Interventions
DRUG

TAK-659

TAK-659 Tablets.

DRUG

Nivolumab

Nivolumab intravenous infusion.

Trial Locations (22)

2114

Massachusetts General, Boston

14263

Roswell Park, Buffalo

19111

Fox Chase, Philadelphia

20089

Istituto di Ricovero e Cura a Carattere Scientifico - Istituto Clinico Humanitas (Humanitas Research, Milan

20132

Ospedale San Raffaele, Milan

22031

US Oncology, Fairfax

28007

Hospital General Universitario Gregorio Maranon, Madrid

28034

Hospital Universitario Ramon y Cajal, Madrid

29010

Hospital Clinico Universitario Virgen de la Victoria, Málaga

30322

Emory, Atlanta

37007

Consejo Superior de Investigaciones Cientificas (CSIC) - Centro de Investigacion del Cancer (CIC), Salamanca

37232

Vanderbilt, Nashville

41124

Azienda Ospedaliero - Universitaria di Modena Policlinico, Modena

46009

Hospital Universitario La Fe, Valencia

46010

Hospital Clinico Universitario de Valencia (CHUV), Valencia

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l, Meldola

48201

Barbara Ann Karmanos, Detroit

53100

Azienda Ospedaliera Universitaria Senese - Policlinico Santa Maria Alle Scotte, Siena

75002

Mary Crowley Research Centers, Dallas

92093

UCSD, La Jolla

NE7 7DN

The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital - Northern Centre for Canc, Newcastle upon Tyne

SO16 6YD

University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY